Drugs / AZD4956
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07446855 | Mar 2026 → Mar 2030 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4956 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07446855 ↗ |
| Route | Oral | “AZD4956 will be administered orally.” NCT07446855 ↗ |